ArticleFrontiers in oncology2026
Bulk and single-cell RNA sequencing data identified HMGB3 of chromatin regulators as a breast cancer biomarker associated with the cell cycle.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chromatin regulators (CRs) have been reported to modulate tumorigenesis and progression in multiple pathophysiological processes, but little is known about theirs role and association with the immune microenvironment in breast cancer (BRCA). Methods: This study identified differential CRs gene expression in BRCA using transcriptome sequencing data and single-cell RNA sequencing data. We investigated the biological function of HMGB3 gene using western blot, transwell assay and immunohistochemistry (IHC). Results: In this research, eleven CRs were discovered and utilized to create a prognostic model. Using median risk scores, patients were sorted into high- and low-risk groups. The nomogram created from this model precisely predicted overall survival (OS). Low-risk patients had notably higher immune cells infiltrating. IHC provided additional evidence that the expression levels of HMGB3 are closely linked to BRCA. Conclusion: Based on bioinformatics analysis of the prognostic value of CRs in BRCA, we identified that HMGB3 as a novel target molecule to promote the occurrence and development of BRCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.